Restricted accessResearch articleFirst published online 2024-04
Angiopoietin-Related Protein 4-Transcript 3 Increases the Proliferation,Invasion,and Migration of Hepatocellular Carcinoma Cells and Inhibits Apoptosis
To investigate the functional differences of angiopoietin-related protein 4 (ANGPTL4) transcripts in hepatocellular carcinoma (HCC) cells. By transfecting ANGPTL4-Transcript 1 and ANGPTL4-Transcript 3 overexpression vectors into HepG2 and Huh7 cell lines with ANGPTL4 knockdown, the effects of overexpression of two transcripts on cell viability, invasion, migration, and apoptosis were analyzed. The expression of two transcripts was compared in human liver cancer tissue, and their effects on tumor development were validated in vivo experiments in mice. Compared with control, the overexpression of ANGPTL4-Transcript 1 had no significant effect on viability, invasion, healing, and apoptosis of HepG2 and Huh7 cells. However, these two cell lines overexpressing ANGPTL4-Transcript 3 showed remarkably enhanced cell viability, invasive and healing ability, and decreased apoptosis ability. Furthermore, the mRNA level of ANGPTL4-Transcript 3 was significantly increased in human HCC tissues and promoted tumor growth compared with Transcript 1. Different transcripts of gene ANGPTL4 have distinct effects on HCC. The abnormally elevated Transcript 3 with the specific ability of promoting HCC proliferation, infiltration, and migration is expected to become a new biological marker and more precise intervention target for HCC.
Get full access to this article
View all access options for this article.
References
1.
Abou-FaycalC, HatatAS, GazzeriS, et al.Splice variants of the RTK family: Their role in tumour progression and response to targeted therapy. Int J Mol Sci, 2017; 18(2):383; doi: 10.3390/ijms18020383
BaiY, CuiGH, SunXK, et al.Effect of deletion of ANGPTL4 gene on viability, migration and invasion ability and apoptosis of hepatocellular carcinoma cells. Discov Med, 2024. In Press.
4.
BecharaEG, SebestyenE, BernardisI, et al.RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell, 2013; 52(5):720–733; doi: 10.1016/j.molcel.2013.11.010
5.
BraunschweigU, GueroussovS, Plocik AM, et al.Dynamic integration of splicing within gene regulatory pathways. Cell, 2013; 152(6):1252–1269; doi: 10.1016/j.cell.2013.02.034
6.
ChenG, WangJ, LiuZ, et al.Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1. Pancreas, 2008; 37(2):159–164; doi: 10.1097/MPA.0b013e31816618a4
7.
CoelhoMB, SmithCW. Regulation of alternative pre-mRNA splicing. Methods Mol Biol, 2014; 1126:55–82; doi: 10.1007/978-1-62703-980-2_5
8.
DavidCJ, ManleyJL. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev, 2010; 24(21):2343–2364; doi: 10.1101/gad.1973010
9.
de Figueiredo-PontesLL, WongDW, TinVP, et al.Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol, 2014; 9(2):248–253; doi: 10.1097/JTO.0000000000000050
10.
DevarbhaviH, AsraniSK, ArabJP, et al.Global burden of liver disease: 2023 update. J Hepatol, 2023; 79(2):516–537; doi: 10.1016/j.jhep.2023.03.017
FangY, LiX, ChengH, et al.ANGPTL4 regulates lung adenocarcinoma pyroptosis and apoptosis via NLRP3\ASC\Caspase 8 signaling pathway to promote resistance to gefitinib. J Oncol, 2022; 2022:3623570; doi: 10.1155/2022/3623570
13.
GalaupA, CazesA, Le JanS, et al.Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci U S A, 2006; 103(49):18721–18726; doi: 10.1073/pnas.0609025103
14.
GanHK, CvrljevicAN, JohnsTG. The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered. FEBS J, 2013; 280(21):5350–5370; doi: 10.1111/febs.12393
15.
GillRB, DayA, BarstowA, et al.Mammalian Sulf1 RNA alternative splicing and its significance to tumour growth regulation. Tumour Biol, 2012; 33(5):1669–1680; doi: 10.1007/s13277-012-0423-2
16.
GuillaudeauA, DurandK, BessetteB, et al.EGFR soluble isoforms and their transcripts are expressed in meningiomas. PLoS One, 2012; 7(5):e37204; doi: 10.1371/journal.pone.0037204
17.
HataS, NomuraT, IwasakiK, et al.Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer. Oncol Rep, 2017; 38(1):120–128; doi: 10.3892/or.2017.5669
18.
IrimiaM, BlencoweBJ. Alternative splicing: Decoding an expansive regulatory layer. Curr Opin Cell Biol, 2012; 24(3):323–332; doi: 10.1016/j.ceb.2012.03.005
19.
KerenH, Lev-MaorG, AstG. Alternative splicing and evolution: Diversification, exon definition and function. Nat Rev Genet, 2010; 11(5):345–355; doi: 10.1038/nrg2776
20.
KimSH, ParkYY, KimSW, et al.ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res, 2011; 71(22):7010–7020; doi: 10.1158/0008-5472.CAN-11-1262
21.
LadomeryM. Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol, 2013; 2013:463786; doi: 10.1155/2013/463786
22.
LiH, GeC, ZhaoF, et al.Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology, 2011; 2;54(3):910–919; doi: 10.1002/hep.24479
23.
LuZX, HuangQ, ParkJW, et al.Transcriptome-wide landscape of pre-mRNA alternative splicing associated with metastatic colonization. Mol Cancer Res, 2015; 13(2):305–318; doi: 10.1158/1541-7786.MCR-14-0366
24.
MaT, JhamBC, HuJ, et al.Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci U S A, 2010; 107(32):14363–14368; doi: 10.1073/pnas.1001065107
25.
MarzeseDM, Manughian-PeterAO, OrozcoJ, et al.Alternative splicing and cancer metastasis: Prognostic and therapeutic applications. Clin Exp Metastasis, 2018; 35(5–6):393–402; doi: 10.1007/s10585-018-9905-y
26.
MoldogazievaNT, MokhosoevIM, ZavadskiySP, et al.Proteomic profiling and artificial intelligence for hepatocellular carcinoma translational medicine. Biomedicines, 2021; 9(2):159; doi: 10.3390/biomedicines9020159
27.
NakayamaT, HirakawaH, ShibataK, et al.Expression of angiopoietin-like 4 (ANGPTL4) in human colorectal cancer: ANGPTL4 promotes venous invasion and distant metastasis. Oncol Rep, 2011; 25(4):929–935; doi: 10.3892/or.2011.1176
28.
NgKT, XuA, ChengQ, et al.Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma. Mol Cancer, 2014; 13:196; doi: 10.1186/1476-4598-13-196
29.
NilsenT W, GraveleyBR. Expansion of the eukaryotic proteome by alternative splicing. Nature, 2010; 463(7280):457–463; doi: 10.1038/nature08909
30.
OheK, HagiwaraM. Modulation of alternative splicing with chemical compounds in new therapeutics for human diseases. ACS Chem Biol, 2015; 10(4):914–924; doi: 10.1021/cb500697f
31.
Okochi-TakadaE, HattoriN, TsukamotoT, et al.ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene, 2014; 33(17):2273–2278; doi: 10.1038/onc.2013.174
32.
PadfieldE, EllisHP, KurianKM. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol, 2015; 5:5; doi: 10.3389/fonc.2015.00005
33.
SaltonM, KasprzakWK, VossT, et al.Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun, 2015; 6:7103; doi: 10.1038/ncomms8103
34.
WangD, LiangW, HuoD, et al.SPY1 inhibits neuronal ferroptosis in amyotrophic lateral sclerosis by reducing lipid peroxidation through regulation of GCH1 and TFR1. Cell Death Differ, 2023; 30(2):369–382.
35.
WangY, ChenD, QianH, et al.The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell, 2014; 26(3):374–389; doi: 10.1038/s41418-022-01089-7
36.
XiaoS, Nai-DongW, Jin-XiangY, et al.ANGPTL4 regulate glutamine metabolism and fatty acid oxidation in nonsmall cell lung cancer cells. J Cell Mol Med, 2022; 26(7):1876–1885; doi: 10.1111/jcmm.16879
37.
YangX, Coulombe-HuntingtonJ, KangS, et al.Widespread expansion of protein interaction capabilities by alternative splicing. Cell, 2016; 164(4):805–817; doi: 10.1016/j.cell.2016.01.029
38.
ZhangH, WeiS, NingS, et al.Evaluation of TGFbeta, XPO4, elF5A2 and ANGPTL4 as biomarkers in HCC. Exp Ther Med, 2013; 5(1):119–127; doi: 10.3892/etm.2012.750
39.
ZhangH, WongCC, WeiH, et al.HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene, 2012; 31(14):1757–1770; doi: 10.1038/onc.2011.365
40.
ZhangJ, ManleyJL. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov, 2013; 3(11):1228–1237; doi: 10.1158/2159-8290.CD-13-0253
ZhaoJ, LiuJ, WuN, et al.ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer. Oncol Lett, 2020; 20(3):2499–2505; doi: 10.3892/ol.2020.11768
43.
ZhengX, LiuR, ZhouC, et al.ANGPTL4-mediated promotion of glycolysis facilitates the colonization of fusobacterium nucleatum in colorectal cancer. Cancer Res, 2021; 81(24):6157–6170; doi: 10.1158/0008-5472.CAN-21-2273
44.
ZhouX, LiX, ChengY, et al.BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun, 2014; 5:4581; doi: 10.1038/ncomms5581
45.
ZhuP, TanMJ, HuangRL, et al.Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell, 2011; 19(3):401–415; doi: 10.1016/j.ccr.2011.01.018
46.
ZhuX, ZhangX, GuW, et al.ANGPTL4 suppresses the profibrogenic functions of atrial fibroblasts induced by angiotensin II by up-regulating PPARγ. Iran J Basic Med Sci, 2023; 26(5):587–593; doi: 10.22038/IJBMS.2023.69196.15077
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
